Trading Statement InPublic Trading Statement


Trading Update

DXS International plc (“DXS”), the healthcare information and digital clinical decision support systems provider, is pleased to announce a trading update. The Company announced on 23 October 2019 that it has again received accreditation for the new GPIT Futures framework agreement, the successor to the current GPSoC2 central NHS funding. The GP IT Futures programme, which begins in January 2020, is a critical enabler for taking primary care towards the requirements set out in the NHS Long Term Plan and the five year framework for GP contract reform. Following this accreditation the company is in the process of gaining final approval for each of our four solutions to be listed on the NHS catalogue.

One exciting initiative that GPIT Futures is bringing to suppliers including DXS is by introducing GP Connect. The GP Connect programme will enable clinicians in different care settings, using solutions such as those which DXS offers, to communicate with one another providing complete interoperability with significant benefits to both patients and clinicians.

Having committed approximately £4 million of mainly internally generated funds into our new products and services during the past four years DXS is well positioned to generate considerable revenue growth from the NHS, other UK target users and overseas opportunities.

Although at an early stage, the Company’s three new Long-Term Condition Expert solutions, are all currently receiving positive responses from our pilot sites, where they are being thoroughly tested.  These new solutions are designed to provide both users (clinicians) and healthcare funders (e.g. NHS) with significant returns by saving valuable clinician time and reducing hospital admissions, as well as improving patient outcomes. It is this message which underpins our sales and marketing strategy.

Our strategic marketing campaign includes digital marketing and social media, conferences and is heavily weighted on referrals from satisfied customers.

The sales and marketing strategy in the UK will focus on our current key solution:

  • DXS Point of Care, a best-of-breed Clinical Decision Support solution that includes automatic provision of decision support as part of clinician workflow and a comprehensive knowledge base and content rich pathways. In line with the NHS strategy, we are in the process of building the new web-based solution which will ultimately replace the current version. This new solution is planned to offer users “smart templates” which will provide users with an increased return on their investment.

and the following new solutions to be launched shortly:

  • CompleteCare, a complete, best evidence medicine clinical template toolset with analytics and reporting features designed to free-up time and maximise return in general practice;
  • ExpertCare, a digital medicines optimisation solution designed to simplify complex medicines prescribing using expert algorithms that empowers nurses and pharmacists to manage complex hypertensive patients saving GP practices and the NHS thousands of pounds per annum; and
  • MyVytalCare, a comprehensive long-term condition management platform that digitally connects doctors and patients and improves condition control and treatment outcomes while saving practices time. 

David Immelman, DXS CEO commented:

“The official launch of these new products and services is planned for early 2020. To ensure success the Company is in the process of reviewing its fundraising options to enable investment into sales, marketing and development.

In addition to the above, the Company is considering moving to AIM in the medium term. It is anticipated that this will facilitate additional funding for our planned international expansion.

Revenue streams, both locally and internationally, are anticipated to continue as a combination of recurring revenue from subscriptions from users and healthcare payers, as well as promotional revenue from the pharmaceutical industry who are seeking new innovative ways of reaching their markets.”

The Directors of DXS International plc accept responsibility for this announcement.


David Immelman   (Chief Executive)
DXS International plc
01252 719800 

Corporate Advisor

City & Merchant
David Papworth

020 7101 7676


Corporate Broker

Hybridan LLP
Claire Louise Noyce

020 3764 2341


Note to Editors:

About DXS

DXS International presents up to date treatment guidelines and recommendations, from Clinical Commissioning Groups and other trusted NHS sources, to doctors, nurses, and pharmacists in their workflow and during the patient consultation. This effective clinical decision support ultimately translates to improved healthcare outcomes delivered more cost effectively which should significantly contribute towards the NHS achieving its projected efficiency savings.

11 November 2019